Virtual ACC 2020 | PRONOMOS: Rivaroxaban Superior to Enoxaparin in Orthopedic Surgery

According to this new study presented virtually at the suspended American College of Cardiology (ACC) 2020 Scientific Session and published simultaneously in the New England Journal of Medicine (NEJM), rivaroxaban is more effective than enoxaparin in preventing venous thromboembolism during a period of immobilization after nonmajor orthopedic surgery of a lower limb.

Pronomos: Rivaroxaban

After an orthopedic surgery, there is a transitory period of reduced mobility during which the risk of deep vein thrombosis must be prevented; so far, enoxaparin was the best option for this. The efficacy of that drug is undisputed, but its uncomfortable administration, particularly for patients on bedrest at their homes, made us continuously seek for an option that was at least noninferior.

This international double-blind, parallel-group, noninferiority study randomized patients undergoing nonmajor orthopedic surgery of a lower limb to rivaroxaban or enoxaparin.

The efficacy endpoint was a composite of symptomatic distal or proximal deep vein thrombosis, pulmonary embolism or thrombosis-related death during the treatment period, or asymptomatic deep vein thrombosis. Researchers planned to test for superiority if rivaroxaban turned out to be noninferior.


Read also: Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease.


The safety endpoint included major bleeding (fatal, critical, clinically evident bleeding, or surgical bleeding requiring a reintervention) and nonmajor clinically relevant bleeding.

The study enrolled 3604 patients; the primary endpoint rate was 0.2% for rivaroxaban vs. 1.1% for enoxaparin (p < 0.001 for noninferiority and p = 0.01 for superiority).

The rates for major bleeding were practically identical: 1.1% vs. 1%, respectively.


Read also: Virtual ACC 2020 | TWILIGHT-DM: Ticagrelor Monotherapy in Diabetic Patients.


This study represents a new landmark in the history of prevention against deep vein thrombosis, with a drug that is both much more comfortable for patients as regards the route of administration and more effective, without compromising its safety.

pronomos

Original Title: Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.

Reference: C. Marc Samama et al. New England Journal of Medicine 2020, online before print y presentado simultáneamente en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...